Use of direct-acting antivirals to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.
Use of statins appears to reduce the risk of developing hepatocellular carcinoma in patients with nonalcoholic fattly liver disease (NAFLD), whereas hypertension conferred a risk increase, according to a retrospective case-control study.
Poor health literacy, functional status and number of daily medications are significantly associated with inadequate bowel preparation, which is a problem that accounts for the reduced yield of screening and increased healthcare cost, according to a study in a tertiary care setting.
The efficacy of ilaprazole 5 mg appears to be on a par with rabeprazole 10 mg in treating duodenal ulcer, a study has shown. In addition, there is a dose-effect relationship between 5- and 10-mg ilaprazole.
The association between domperidone at commonly prescribed doses of 30–80 mg/d and QTc prolongation is observed in only 6 percent of patients, with no case of QT interval reaching the point considered to be clinically significant, reports a study.
Mortality, length of stay (LOS) and hospital charges are significantly higher in chronic liver disease (CLD) patients with fractures, a recent study has shown. These findings are also associated with increased infection, bleeding and poorer wound healing.
New drug applications approved by US FDA as of 16 - 30 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.